Emerging applications of stereotactic body radiotherapy

Future Oncology

Volumn 10, Issue 7, 2014, Pages 1299-1310

  Lo, Simon S ^a   Loblaw, Andrew ^b   Chang, Eric L ^c   Mayr, Nina A ^d   Teh, Bin S ^e   Huang, Zhibin ^f   Yao, Min ^a   Ellis, Rodney J ^a   Biswas, Tithi ^a   Sohn, Jason W ^a   Machtay, Mitchell ^a   Sahgal, Arjun ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

Author keywords

adrenal metastasis; boost for lung cancer; breast cancer; gynecological cancer; head and neck cancer; pancreatic cancer; prostate cancer; renal cell carcinoma; spinal cord compression; stereotactic body radiotherapy

Indexed keywords

ADRENAL METASTASIS; ADVANCED CANCER; BREAST CANCER; CANCER LOCALIZATION; CANCER RADIOTHERAPY; FOLLOW UP; GYNECOLOGIC CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MEDICAL LITERATURE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPINAL CORD COMPRESSION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; NEOPLASMS; PROCEDURES; RADIOSURGERY;

HUMANS; NEOPLASMS; RADIOSURGERY;

EID: 84903125856     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.13     Document Type: Review

References (78)

1. Lo SS, Fakiris AJ, Chang EL et al. Stereotactic body radiation therapy: a novel treatment modality Nat. Rev. Clin. Oncol. 7(1), 44-54 (2010).
2. Siddiqui F, Raben D, Lu JJ et al. Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev. Anticancer Ther. 11(9), 1429-1436 (2011).
3. Lo SS, Cardenes HR, Teh BS et al. Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev. Anticancer Ther. 8(12), 1939-1951 (2008).
4. Ishiyama H, Teh BS, Lo SS et al. Stereotactic body radiation therapy for prostate cancer. Future Oncol. 7(9), 1077-1086 (2011).
5. Berber B, Sanabria JR, Braun K et al. Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. Expert Rev. Anticancer Ther. 13(4), 481-487 (2013).
6. Mayr NA, Huang Z, Sohn JW et al. Emerging application of stereotactic body radiation therapy for gynecologic malignancies. Expert Rev. Anticancer Ther. 11(7), 1069-1075 (2011).
7. Ryu S, Rock J, Jain R et al. Radiosurgical decompression of metastatic epidural compression. Cancer 116(9), 2250-2257 (2010).
8. Bondiau PY, Bahadoran P, Lallement M et al. Robotic stereotactic radioablation concomitant with neo-adjuvant chemotherapy for breast tumors. Int. J. Radiat. Oncol. Biol. Phys. 75(4), 1041-1047 (2009).
9. Bondiau PY, Courdi A, Bahadoran P et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 85(5), 1193-1199 (2013).
10. Feddock J, Arnold SM, Shelton BJ et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 85(5), 1325-1331 (2013).
11. Hara W, Loo BW Jr, Goffnet DR et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 393-400 (2008).
12. Chua DT, Wu SX, Lee V, Tsang J. Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis. Head Neck Oncol. 1, 13 (2009).
13. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am. J. Clin. Oncol. 34(2), 165-172 (2011).
14. Cengiz M, Ozyigit G, Yazici G et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 81(1), 104-109 (2011).
15. Kodani N, Yamazaki H, Tsubokura T et al. Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J. Radiat. Res. 52(1), 24-31 (2011).
16. Unger KR, Lominska CE, Deeken JF et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 77(5), 1411-1419 (2010).
17. Siddiqui F, Patel M, Khan M et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int. J. Radiat. Oncol. Biol. Phys. 74(4), 1047-1053 (2009).
18. Lartigau EF, Tresch E, Thariat J et al. Multi institutional Phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother. Oncol. 109(2), 281-285 (2013).
19. Roh KW, Jang JS, Kim MS et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1348-1355 (2009).
20. Rwigema JC, Heron DE, Ferris RL et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy Am. J. Clin. Oncol. 34(4), 372-379 (2011).
21. McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int. J. Radiat. Oncol. Biol. Phys. 82(3), 1083-1089 (2012).
22. Yazici G, Sanl TY, Cengiz M et al. A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers. Radiat. Oncol. 8(1), 242 (2013).
23. Atwell TD, Schmit GD, Boorjian SA et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am. J. Roentgenol 200(2), 461-466 (2013).
24. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 113(10), 2671-2680 (2008).
25. Svedman C, Sandstrom P, Pisa P et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 45(7), 870-875 (2006).
26. Wersall PJ, Blomgren H, Lax I et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77(1), 88-95 (2005).
27. Kaplan ID, Redrosa I, Martin C. Results of a Phase I dose escalation study of stereotactic radiosurgery for primary renal tumors. Int. J. Radiat. Oncol. Biol. Phys. 78, S191 (2010).
28. Beitler JJ, Makara D, Silverman P, Lederman G. Defnitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am. J. Clin. Oncol. 27(6), 646-648 (2004).
29. Ellis RJ, Patel RB, Kunos C et al. Stereotactic radiosurgery for renal cancer: Phase I safety and toxicity Int. J. Radiat. Oncol. Biol. Phys. 84(3), S119 (2012).
30. Ponsky LE, Mahadevan A, Gill IS, Djemil T, Novick AC. Renal radiosurgery: initial clinical experience with histological evaluation. Surg. Innov. 14(4), 265-269 (2007).
31. Teh B, Bloch C, Galli-Guevara M et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed. Imaging Interv. J. 3(1), e6 (2007).
32. Svedman C, Karlsson K, Rutkowska E et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney Acta Oncol. 47(8), 1578-1583 (2008).
33. Pahlajani N, Ruth KJ, Buyyounouski MK et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with gleason score 8 to 10 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 1949-1956 (2012).
34. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1405-1418 (2009).
35. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5, 969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int. J. Radiat. Oncol. Biol. Phys. 82(1), e17-e24 (2012).
36. Thames HD, Kuban D, Levy LB et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother. Oncol. 96(1), 6-12 (2010).
37. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat. Oncol. 8(1), 118 (2013).
38. Kupelian P, Katz Aj, Freeman D et al. Long-term effcacy of stereotactic body radiotherapy for localized prostate cancer: a multi-institutional pooled analysis. J. Clin. Oncol. 31(Suppl. 6), Abstract 9 (2013).
39. Loblaw A, Cheung P, DAlimonte, L et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother. Oncol. 107(2), 153-158 (2013).
40. Pham HT, Song G, Badiozamani K et al. Five-year outcome of stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP) for patients with low-risk prostate cancer. Int. J. Rad. Onc. Biol. Phys. 78(3 Suppl.), S58 (2010).
41. Morris WJ, Keyes M, Spadinger I et al. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. Cancer 119(8), 1537-1546 (2013).
42. Morton G, Loblaw A, Cheung P et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother. Oncol. 100(3), 463-467 (2011).
43. Boike TP, Lotan Y, Cho LC et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J. Clin. Oncol. 29(15), 2020-2026 (2011).
44. Quon HC, Loblaw DA, Cheung P et al. Dose escalation of 5-fraction radiation therapy for prostate cancer: quality of life comparison of 2 prospective trials. Int. J. Rad. Onc. Biol. Phys. 84, S148 (2012).
45. Sethukavalan P, Cheung P, Tang CI et al. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefts of hypofractionated over conventionally fractionated radiotherapy. Can J. Urol. 19(2), 6165-6169 (2012).
46. Shiue K, Song A, Teh BS et al. Stereotactic body radiation therapy for metastasis to the adrenal glands. Expert Rev. Anticancer Ther. 12(12), 1613-1620 (2012).
47. Chawla S, Chen Y, Katz AW et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 71-75 (2009).
48. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther. Onkol. 187(4), 245-251 (2011).
49. Scorsetti M, Alongi F, Filippi AR et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 51(5), 618-623 (2012).
50. Scorsetti M, Mancosu P, Navarria P et al. Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther. Onkol. 187(4), 238-244 (2011).
51. Torok J, Wegner RE, Burton SA, Heron, DE: Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 7(1), 145-151 (2011).
52. Ahmed KA, Barney BM, Macdonald OK et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am. J. Clin. Oncol. 36(5), 509-513 (2013).
53. Casamassima F, Livi L, Masciullo S et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 919-923 (2012).
54. Rudra S, Malik R, Ranck MC et al. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol. Cancer Res. Treat. 12 (3), 217-224 (2013).
55. Katoh N, Onimaru R, Sakuhara Y et al. Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother. Oncol. 87(3), 418-424 (2008).
56. Schellenberg D, Goodman KA, Lee F et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 72(3), 678-686 (2008).
57. Koong AC, Christofferson E, Le QT et al. Phase II study to assess the effcacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 63(2), 320-323 (2005).
58. Koong AC, Le QT, Ho A et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 58(4), 1017-1021 (2004).
59. Schellenberg D, Kim J, Christman-Skieller C et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 81(1), 181-188 (2011).
60. Hoyer M, Roed H, Sengelov L et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother. Oncol. 76(1), 48-53 (2005).
61. Mahadevan A, Miksad R, Goldstein M et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int. J. Radiat. Oncol. Biol. Phys. 81(4), e615-e622 (2011).
62. Chuong MD, Springett GM, Freilich JM et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int. J. Radiat. Oncol. Biol. Phys. 86(3), 516-522 (2013).
63. Gurka MK, Collins SP, Slack R et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat. Oncol. 8, 44 (2013).
64. Herman JM, Chang DT, Goodman KA et al. A Phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma. J. Clin. Oncol. 30(Suppl.), Abstract 4045 (2012).
65. Mahadevan A, Jain S, Goldstein M et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(3), 735-742 (2010).
66. Polistina F, Costantin G, Casamassima F et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann. Surg. Oncol. 17(8), 2092-2101 (2010).
67. Rwigema JC, Parikh SD, Heron DE et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am. J. Clin. Oncol. 34(1), 63-69 (2011).
68. Didolkar MS, Coleman CW, Brenner MJ et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of frst 85 patients. J. Gastrointest. Surg. 14(10), 1547-1559 (2010).
69. Higginson DS, Morris DE, Jones EL, Clarke-Pearson D, Varia MA. Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology Gynecol. Oncol. 120(3), 404-412 (2011).
70. Jorcano S, Molla M, Escude L et al. Hypofractionated extracranial stereotactic radiotherapy boost for gynecologic tumors: a promising alternative to high-dose rate brachytherapy Technol. Cancer Res. Treat. 9(5), 509-514 (2010).
71. Kubicek GJ, Xue J, Xu Q et al. Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer. Biomed Res. Int. 2013, 898953 (2013).
72. Kunos CA, Brindle J, Waggoner S et al. Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies. Front Oncol. 2, 181 (2012).
73. Jin R, Rock J, Jin JY et al. Single fraction spine radiosurgery for myeloma epidural spinal cord compression. J. Exp. Ther. Oncol. 8(1), 35-41 (2009).
74. Suh JH, Balagamwala EH, Reddy CA et al. The use of spine stereotactic body radiation therapy for the treatment of spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 84(3), S631 (2012).
75. Sharp HJ, Brown P, Settle SH et al. Feasibility of radiosurgical decompression of metastatic epidural spinal cord compression (MESCC) in nonoperable patients Int. J. Radiat. Oncol. Biol. Phys. 84(3), S282 (2012)
76. American Society for Therapeutic Radiology and Oncology: ASTRO Model Policies-Stereotactic Body Radiation Therapy (SBRT). www.astro.org/ uploadedFiles/Main-Site/Practice-Management/Reimbursement/ 2013HPcoding%2020guidelines-SBRT-Final.pdf
77. RTOG 0938 Protocol Information. www.rtog.org/ClinicalTrials/ ProtocolTable/StudyDetails.aspx?study=0938
78. Cox JD. Are the results of RTOG 0617 mysterious? Int. J. Radiat. Oncol. Biol. Phys. 82(3), 1042-1044 (2012).